Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 26;3(4):375-389.
doi: 10.1007/s43657-022-00068-9. eCollection 2023 Aug.

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease

Affiliations

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease

Mei Tian et al. Phenomics. .

Abstract

Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography (PET) has become increasingly important in medical practice for patients with AD. To integrate and update previous guidelines in the field, a task group of experts of several disciplines from multiple countries was assembled, and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals, focusing on clinical scenarios, patient preparation, administered activities, as well as image acquisition, processing, interpretation and reporting. In addition, expert opinions, practices, and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated. With the increasing availability of amyloid PET imaging, a complete and standard pipeline for the entire examination process is essential for clinical practice. This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.

Keywords: Alzheimer’s disease; Amyloid; Brain imaging; Expert consensus; Positron emission tomography (PET).

PubMed Disclaimer

Conflict of interest statement

Conflicts of InterestThe authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The flowchart of the recommended examination procedures in performing amyloid PET scanning and reporting
Fig. 2
Fig. 2
The visual assessment algorithm of amyloid PET images includes color scale of displayed images (a), observation sequence (b), assessment of image quality (c), negative-image signs (d) and positive-image signs (e)

Similar articles

Cited by

References

    1. Akamatsu G, Ikari Y, Ohnishi A, Matsumoto K, Nishida H, Yamamoto Y, et al. Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. EJNMMI Res. 2019;9(1):91. doi: 10.1186/s13550-019-0561-2. - DOI - PMC - PubMed
    1. Arnaoutoglou NA, O'Brien JT, Underwood BR. Dementia with Lewy bodies - from scientific knowledge to clinical insights. Nat Rev Neurol. 2019;15(2):103–112. doi: 10.1038/s41582-018-0107-7. - DOI - PubMed
    1. Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8(1):107. doi: 10.1186/s13550-018-0456-7. - DOI - PMC - PubMed
    1. Beach TG, Thal DR, Zanette M, Smith A, Buckley C. Detection of Striatal amyloid plaques with [18F]flutemetamol: validation with postmortem histopathology. J Alzheimers Dis. 2016;52(3):863–873. doi: 10.3233/JAD-150732. - DOI - PubMed
    1. Bourgeat P, Doré V, Doecke J, Ames D, Masters CL, Rowe CC, et al. Non-negative matrix factorisation improves centiloid robustness in longitudinal studies. NeuroImage. 2021;226:117593. doi: 10.1016/j.neuroimage.2020.117593. - DOI - PMC - PubMed

LinkOut - more resources